Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases

Abstract

The risk of lung cancer is high in patients with interstitial lung disease (ILD). It was reported that tumor markers was increased in ILD patients. The serum levels of CEA, CA19-9, CA125 and NSE were measured in 58 ILD combines lung cancer (ILD-CA) patients, 632 ILD patients and 632 control subjects. The analysis of covariance, multiple linear regression, Logistic regression analysis and ROC curve were used for statistical analyses. The serum levels of CEA, CA19-9, CA125 and NSE showed decrement tendency in ILD-CA group, ILD group and the control group (P <0.01). They were higher in patients with ILD-CA than those in patients with ILD and control (P <0.05). The levels of CEA and CA125 in ILD group were higher than the control group (P <0.01). The ILD group included idiopathic pulmonary fibrosis (IPF) subgroup of 214 cases, non-IPF idiopathic interstitial pneumonia (nonIPF-IIP) subgroup of 97 patients, collagen vascular disease associated ILD (CVD-ILD) subgroup of 163 cases, and other ILD subgroup of 158 cases. The serum levels of CEA, CA19-9 and CA125 were the highest in patients with IPF than the other three subgroups of ILD (P <0.01). Adjusting the confounding factors such as gender, age and smoking condition, the risk of ILD-CA increased with the elevation of CEA and CA125. This study provides that the elevation of serum tumor markers in patients with ILD-CA is a common sign, and is also an important sign in patients with ILD, especially in patients with IPF. Incidence of lung cancer is increased in ILD patients with elevation of the serum levels of CEA and CA125.

Rating:

Share or cite this content

Citations should be made in the following way:
J. Liu, H. Dai, L. Liang, L. Peng, J. Jiang (Beijing, China). Elevation of serum tumor markers in patients with interstitial lung disease. Eur Respir J 2011; 38: Suppl. 55, 4776

Member's Comments

No comment yet.

Related content which might interest you: Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Usefulness of serum bird specific antibody levels in patients with interstitial pneumonia Source: International Congress 2016 – Orphan diseases II Year: 2016 Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Tumor markers in bronchial secretions and serum in patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Increased cytokeratin-19 expression in fibrotic interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 A clinicopathological review of interstitial pneumonia with marked IgG4 positive plasma cells infiltration Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009 Circulating fibrocytes in interstitial lung disease Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Elevation of serum napsin A levels in patients with hypersensitive pneumonia Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Serum heat shock protein 47 levels in patients with drug induced lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013